Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SPRC - SciSparc Ltd.


0.3196
0.003   0.814%

Share volume: 227,204
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.03%

PREVIOUS CLOSE
CHG
CHG%

$0.32
0.00
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
0.82%
1 Month
-13.62%
3 Months
-13.62%
6 Months
-13.62%
1 Year
-13.62%
2 Year
-13.62%
Key data
Stock price
$0.32
P/E Ratio 
N/A
DAY RANGE
$0.31 - $0.34
EPS 
N/A
52 WEEK RANGE
$0.30 - $0.40
52 WEEK CHANGE
-$13.62
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$310,682
AVERAGE 30 VOLUME 
$291,686
Company detail
CEO: Oz Adler
Region: US
Website: scisparc.com
Employees: 4
IPO year: 2021
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

SciSparc Ltd. develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation. SCi-160 for the. treatment of pain; SCII-210 for the. treatment of autism spectrum disorder and epilepsy. The company was formerly known as Therapix Biosciences.

Recent news